Drug Profile
Olmesartan medoxomil/rosuvastatin
Alternative Names: DWJ 1276; Olmesartan/rosuvastatin; Olostar; Rosuvastatin/olmesartan medoxomil; ST-101 - Stocosil; ST-102 - StocosilLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Developer Daewoong Pharmaceutical; Daiichi Sankyo Korea; Stocosil
- Class Antihyperlipidaemics; Antihypertensives; Fluorobenzenes; Imidazoles; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 27 Sep 2021 No development reported - Phase-II for Hyperlipidaemia in USA (PO)
- 27 Sep 2021 No development reported - Phase-II for Hypertension in USA (PO)
- 05 Feb 2019 Chemical structure information added